Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Orgenesis (ORGS), 546% surge in interest
• Cyclacel Pharmaceuticals (CYCC), 326% surge in interest
• Amicus Therapeutics (FOLD), 24% surge in interest

Pipeline and key clinical candidates for these companies:

Orgenesis is a biotech company that says it has been “committed to unlocking the potential of cell and gene therapies since 2012 as well as a paradigm-shifting decentralized approach to processing since 2020.” Orgenesis is focusing on advancing its CGTs toward eventual commercialization, while “partnering with key industry stakeholders to provide a rapid, globally harmonized pathway for these therapies to reach and treat a larger number of patients more cost effectively and with better outcomes through great science and decentralized production,” the company states.

Cyclacel is a clinical-stage, biopharmaceutical company developing cancer medicines based on cell cycle, transcriptional regulation, epigenetics and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the epigenetic/anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.

Recent news on these stocks:

October 21

Orgenesis announced that its common stock will begin trading on the OTCQX Best Market under the ticker symbol “ORGS” following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company’s failure to meet the required stockholders’ equity threshold. Orgenesis plans to attempt to resolve the deficiency and reapply for a Nasdaq listing as soon as practical.

October 17

Amicus Therapeutics announced that it has entered into a License Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals (TEVA). This Agreement resolves the patent litigation brought by Amicus in response to Teva’s Abbreviated New Drug Application, ANDA, seeking approval to market a generic version of GALAFOLD 123mg capsules prior to expiration of the applicable patents. Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD in the United States beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration and unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding GALAFOLD patents pending in the U.S. District Court for the District of Delaware.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.